2. Academic Validation
  3. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

  • Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00819-20. doi: 10.1128/AAC.00819-20.
Sangeun Jeon  # 1,  Meehyun Ko  # 1,  Jihye Lee 1,  Inhee Choi 2,  Soo Young Byun 3,  Soonju Park 3,  David Shum 3,  Seungtaek Kim 4
Affiliations

Affiliations

  • 1 Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
  • 2 Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea.
  • 3 Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
  • 4 Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea seungtaek.kim@ip-korea.org.
  • # Contributed equally.
PMID: 32366720 DOI: 10.1128/AAC.00819-20
Abstract

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential Antiviral drug candidates against SARS-CoV-2 Infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.

Keywords

COVID-19; FDA-approved drug; SARS-CoV-2.

Figures
Products